<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SANOFI</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SANOFI</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="sanofi-india-limited" class="section level1">
<h1>Sanofi India Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SANOFI.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="sanofi-india-limited-sanofi-analysis-headwinds-tailwinds-growth-prospects-and-key-risks" class="section level3">
<h3>Sanofi India Limited (SANOFI) Analysis: Headwinds, Tailwinds, Growth Prospects, and Key Risks</h3>
<p>Sanofi India Limited (SIL), a pharma company focused post-demerger on its diabetes/insulin franchise and legacy portfolios (CV, CNS, OAD via partnerships), reported Q3/9M 2025 results showing resilient profitability amid top-line pressures. Domestic sales grew modestly (+3-5% YoY/QoQ), driven by insulin momentum and partnerships, but exports declined sharply. Strategic transformation emphasizes customer-centric, AI/digital ops for sustainable growth in India’s diabetes market. Below is a structured summary based on the earnings call, financials, presentation, and disclosures.</p>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6><strong>Tailwinds (Positive Catalysts)</strong></h6>
<ul>
<li><strong>Margin Expansion &amp; OPEX Efficiency</strong>: Significant OPEX reduction (-30% QoQ in personnel/other costs), improving PBT margins from 23% (Q3’24) to 29% (Q3’25). YTD PBT +10% despite flat revenue. Restructuring (e.g., Emcure partnership for OAD) unlocks savings; run-rate employee costs stabilizing lower.</li>
<li><strong>Diabetes Franchise Strength</strong>: Leadership in insulin (Lantus ~50% glargine share, Toujeo 12%; total 62-63%). Soliqua (GLP-1 + insulin glargine) gaining traction in premix segment with clinical evidence and digital outreach. Management sees early insulinization as resilient vs. GLP-1s.</li>
<li><strong>Partnership Model Success</strong>: Legacy CV/CNS/OAD growing +2% YTD/+5% Q3 via partners (e.g., Emcure), expanding Tier 2/3 reach without in-house costs. Long-term DCF justifies shift despite initial top-line dip.</li>
<li><strong>Digital/AI Transformation</strong>: AI-driven tools (forecasting ±1% accuracy, next-best sales actions, regulatory streamlining) boosting efficiency across sales, finance, ops. Positions SIL as “future-ready” for high-growth diabetes market.</li>
<li><strong>Capital Return &amp; Leadership</strong>: Rs 75/share interim dividend (record date Nov 7, 2025). New MD Deepak Arora (30+ yrs exp.) appointed, signaling stability post-interim MD transition.</li>
<li><strong>No Material Legal Impact</strong>: GST amnesty waives ~Rs 5 Cr interest/penalty; retained demand already paid.</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>Headwinds (Challenges)</strong></h6>
<ul>
<li><strong>Top-Line Pressure from Exports</strong>: Exports (12-13% of sales) down 35-50% due to 2020 Ankleshwar divestment to Zentiva (delayed approvals). Partial offset via Goa ramp-up/Russia/South Africa, but won’t fully recover; low-margin anyway (8% of PBT).</li>
<li><strong>Partnership Transition Drag</strong>: Gross-to-net model reduces reported revenue/pricing vs. prior in-house sales; Q3 domestic flat YoY despite +5% partnerships growth (non-apple-to-apple).</li>
<li><strong>Restructuring Costs</strong>: Exceptional personnel separation (Rs 27 Cr Q3; Rs 273 Mn 9M) from OAD partnership/field force optimization.</li>
<li><strong>Historical Volatility</strong>: Post-demerger (Consumer HC hived off June 2024), top-line appears subdued/volatile; investors noted nervousness.</li>
</ul>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>Growth Prospects</strong></h6>
<ul>
<li><strong>Core Insulin Acceleration (High Confidence)</strong>: 3 pillars – portfolio (Lantus volume, Toujeo U300 public/private push, Soliqua uptake), market expansion (early insulinization awareness, Tier 2/3 digital/public sector), AI orchestration. Management targets “respectable” organic growth &gt; market; diabetes ~50% of domestic sales.</li>
<li><strong>Partnership Leverage</strong>: Year 2-3 ramp-up expected for legacy brands via partners’ networks; sustainable without diluting insulin focus.</li>
<li><strong>Export Stabilization</strong>: New markets (Russia full-year, South Africa) + CMO internalization at Goa; ~81% India/18% Singapore revenue mix to diversify modestly.</li>
<li><strong>India Diabetes Opportunity</strong>: Huge unmet need; biosimilars/GLP-1s (e.g., sema Mar’26) seen as complementary/not substitutive by HCPs. No dilution into new segments/launches till 2026; focus yields 10%+ PBT growth trajectory if trends hold.</li>
<li><strong>No Guidance, But Positive Trends</strong>: Double-digit YTD PBT growth; analysts to forecast ~Rs 2,000 Cr annual sales.</li>
</ul>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q3’25</th>
<th>9M’25</th>
<th>YoY Change</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue</td>
<td>Rs 4,754 Cr</td>
<td>Rs 14,176 Cr</td>
<td>-9% / -5%</td>
</tr>
<tr class="even">
<td>Domestic</td>
<td>+5% QoQ</td>
<td>+3%</td>
<td>Stable+</td>
</tr>
<tr class="odd">
<td>PBT (pre-exc.)</td>
<td>Rs 1,296 Cr (29%)</td>
<td>Rs 3,890 Cr</td>
<td>+15% / +10%</td>
</tr>
</tbody>
</table>
</div>
<div id="key-risks" class="section level6">
<h6><strong>Key Risks</strong></h6>
<table>
<colgroup>
<col width="41%" />
<col width="25%" />
<col width="33%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Details</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Competition</strong></td>
<td>Biosimilars eroding Lantus (now NLEM-priced); GLP-1s (sema’26) delaying insulinization.</td>
<td>Strong innovator positioning (50%+ share intact); Soliqua hybrid appeal; HCP loyalty.</td>
</tr>
<tr class="even">
<td><strong>Revenue Concentration</strong></td>
<td>Diabetes/insulin ~48-50% sales; no new launches 2026.</td>
<td>Partnerships diversify legacy; public sector entry.</td>
</tr>
<tr class="odd">
<td><strong>Export/Regulatory</strong></td>
<td>Delayed approvals, forex volatility; partial recovery only.</td>
<td>Diversifying markets; low PBT reliance (8%).</td>
</tr>
<tr class="even">
<td><strong>Operational</strong></td>
<td>Partnership ramp-up lags; AI/digital execution risks.</td>
<td>Proven early wins (e.g., Soliqua launch).</td>
</tr>
<tr class="odd">
<td><strong>Financial/Legal</strong></td>
<td>Tax litigations (GST retained Rs 17L); thin other income (1%).</td>
<td>Already provisioned; strong balance sheet.</td>
</tr>
<tr class="even">
<td><strong>Execution/Mgmt</strong></td>
<td>New MD approval via postal ballot (Dec’25); no resident India stay (needs govt nod).</td>
<td>Experienced leader; board continuity.</td>
</tr>
<tr class="odd">
<td><strong>Macro</strong></td>
<td>Pricing pressure, generic competition in partnerships.</td>
<td>Focus on premium insulin; OPEX discipline.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook</strong>: SIL’s pivot to lean, insulin-led model is delivering profitability (tailwind-dominant), with growth prospects tied to execution in diabetes/public partnerships. Headwinds (exports/partnerships) are transitional; risks manageable but monitor GLP-1/biosimilar impact. Positive for margins/dividends; top-line reacceleration key for FY26. No forward guidance; invest based on diabetes conviction.</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
